Reconstructed epidermis or skin equivalent with improved barrier function, supplemented by ceramide 7 and 5.5 derivative introduced into culture medium or applied topically in lamellar lipid vesicle formulation

摘要

Producing reconstructed epidermis or a skin equivalent supplemented by at least one ceramide 7 and/or 5.5 derivative (I), comprising introducing (I) into the culture medium for the reconstructed epidermis or skin equivalent, and/or topically treating the surface of the reconstructed epidermis or skin equivalent with a composition (A) based on lamellar lipid vesicles incorporating (I), is new. Producing reconstructed epidermis or a skin equivalent supplemented by at least one ceramide derivative of formula (I) involves: (a) introducing (I) into the culture medium for the reconstructed epidermis or skin equivalent; and/or (b) topically treating the surface of the reconstructed epidermis or skin equivalent with a composition (A) based on lamellar lipid vesicles incorporating (I). [Image] X : H or OH (preferably OH); n : 19-29 (preferably 21-27, especially 21, 22 or 23, particularly 21); m : 9-19 (preferably 9-15, especially 11, 12 or 13, particularly 11). Independent claims are also included for: (1) an aqueous dispersion (A') of vesicles formed by lamellar lipid phases containing (I) and separated by hydrophilic layers; and (2) a skin equivalent or reconstructed skin containing (I; X = H). ACTIVITY : Dermatological; MECHANISM OF ACTION : Skin ceramide profile modulator; increasing skin 6-hydroxy-4-sphingenine (HSG) levels. In tests using Episkin (RTM; reconstructed epidermis), topical application of a niosome formulation containing 0.0315 % ceramide 7 (Ia) gave a level of HSG of 60 ng per cm2 of epidermis, compared with 25 ng/cm2 without treatment or after treatment with a placebo formulation without (Ia).